Tuesday, July 07, 2020 4:30:12 PM
Bucillamine had already gone through a Phase 2 with the FDA. Safety wise Bucillamine has been proven non-toxic at high dosing. Which is what they want to do in the Phase 3 for Covid-19 treatment.
In all likeliness it should be going through the fast track program.
In all likeliness it should be going through the fast track program.
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
